THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.28] ID: TIP-MED-000260

Chlorhexidine Gluconate (0.2% Mouthwash & 4% Surgical Scrub)

Active Ingredient / Scientific Identity: Chlorhexidine Gluconate • Class: Cationic Bisbiguanide Antiseptic & Disinfectant (Persistent Residual Substantivity)

⚖️ Compare Profile
Generic / Entity NameChlorhexidine Gluconate (0.2% Mouthwash & 4% Surgical Scrub) ([12.28])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassCationic Bisbiguanide Antiseptic & Disinfectant (Persistent Residual Substantivity)
Available Dosage FormsMouthwash / Gel: 0.12% w/v, 0.2% w/v; Surgical Scrub: 4% w/v; Alcoholic Skin Prep: 2% w/v in 70% IPA; Neonatal
Regulatory ClassificationNon-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommend
Key Warning & Review DateRenal: Not applicable. • Hepatic: Not applicable.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC or Schedule K Permitted Preparati✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Chlorhexidine Gluconate (0.2% Mouthwash & 4% Surgical Scrub) (TIP-MED-000260, Reference Code [12.28]) is classified under Dermatological & Topical Antiseptic Preparations (Ch 12) as a Cationic Bisbiguanide Antiseptic & Disinfectant (Persistent Residual Substantivity). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.28], p. 168): Hexidine, Clohex, Rexidin (Mouthwash 0.2%), Savlon (with Cetrimide), Microshield (2%/4%) — Strengths & Dosage Forms: Mouthwash / Gel: 0.12% w/v, 0.2% w/v; Surgical Scrub: 4% w/v; Alcoholic Skin Prep: 2% w/v in 70% IPA; Neonatal Umbilical Gel/Solution: 7.1% digluconate (= 4% chlorhexidine); Concentrate (with Cetrimide): 1.5% + 3%.
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.28], p. 168): Hexidine, Clohex, Rexidin (Mouthwash 0.2%), Savlon (with Cetrimide), Microshield (2%/4%) — Strengths & Dosage Forms: Mouthwash / Gel: 0.12% w/v, 0.2% w/v; Surgical Scrub: 4% w/v; Alcoholic Skin Prep: 2% w/v in 70% IPA; Neonatal Umbilical Gel/Solution: 7.1% digluconate (= 4% chlorhexidine); Concentrate (with Cetrimide): 1.5% + 3%.
Dosage Forms & Available Strengths:
Mouthwash / Gel: 0.12% w/v, 0.2% w/v; Surgical Scrub: 4% w/v; Alcoholic Skin Prep: 2% w/v in 70% IPA; Neonatal Umbilical Gel/Solution: 7.1% digluconate (= 4% chlorhexidine); Concentrate (with Cetrimide): 1.5% + 3%.
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Positively charged cationic molecule binds strongly to negatively charged bacterial cell walls and oral/cutaneous strata -> disrupts cytoplasmic membranes and binds to skin/mucosa providing persistent residual antimicrobial activity ('substantivity') for >=6 hours.

4. Therapeutic Indications & Evidence-Supported Uses

  • Gingivitis, oral mucositis, and periodontal plaque control (0
  • 12-0
  • 2% mouthwash)
  • neonatal umbilical cord care (7
  • 1% chlorhexidine digluconate delivering 4% chlorhexidine)
  • pre-operative skin prep and central-line antisepsis (2% in 70% isopropyl alcohol)
  • surgical hand scrub (4%)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adult: Mouthwash (0.2%): Rinse thoroughly with 10 mL undiluted for 1 full minute twice daily and spit out. Skin / Central-Line Prep: Apply 2% alcoholic solution and allow to dry completely before venepuncture/cautery. • Paediatric: Neonatal Umbilical Cord Care (in high-mortality home-birth settings): Apply 4% chlorhexidine daily to umbilical stump during first week of life.

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Not applicable. • Hepatic: Not applicable.
Elimination & Renal Adjustment:
Renal: Not applicable. • Hepatic: Not applicable.
Hepatic Impairment Considerations:
Renal: Not applicable. • Hepatic: Not applicable.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: Direct contact with the brain, meninges, middle ear (perforated tympanic membrane—causes sensorineural deafness!), or eyes (concentrations >0.05% cause severe irreversible corneal endothelial toxicity). • Precautions: Cationic chlorhexidine is inactivated by anionic surfactants—specifically SODIUM LAURYL SULPHATE (SLS) present in almost all standard toothpastes and soaps! Wait at least 30 minutes after brushing teeth with toothpaste before using Chlorhexidine mouthwash. Never put Neonatal 4% Chlorhexidine Umbilical Gel/Drops into the infant's eyes!

Key Clinical Precautions: Renal: Not applicable. • Hepatic: Not applicable.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Reversible extrinsic brown staining of teeth, tongue, and silicate fillings; transient dysgeusia (altered taste/burning tongue); increased tartar.
  • Rare severe IgE-mediated anaphylaxis (especially from chlorhexidine-coated central venous or urinary catheters), corneal ulceration, ototoxicity.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Sodium Lauryl Sulphate (toothpaste) / Soaps / Povidone-iodine / Hypochlorite bleach -> chemical precipitation and inactivation (chlorhexidine + bleach on hospital linen produces permanent dark brown stains)

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Wait at least 30 minutes AFTER brushing teeth with toothpaste before rinsing with Chlorhexidine mouthwash (toothpaste neutralises the medicine); rinse for 60 seconds, spit out, and do not eat or drink for 30 minutes after.
  • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
  • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
  • Geriatric Dispensing Pearl: Schedule: OTC / Non-Schedule | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / BNF 90th Ed

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Mouthwash / Gel: 0.12% w/v, 0.2% w/v; Surgical Scrub: 4% w/v; Alcoholic Skin Prep: 2% w/v in 70% IPA; Neonatal Umbilical Gel/Solution: 7.1% digluconate (= 4% chlorhexidine); Concentrate (with Cetrimide): 1.5% + 3%.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.28] (p. 168)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.